Table 4 Src kinase inhibitor developed by QSAR modification
From: Recent advances in pharmacological diversification of Src family kinase inhibitors
Template | Example of inhibitor | Ref |
|---|---|---|
Azaacridine | N-(4-((5,10-dihydropyrimido[4,5-b]quinolin-4-yl)amino)phenyl)-3-fluorobenza-mide | [29] |
Benzamide | SB163 | [39] |
Indolinone | SU-6656 | [22] |
Nicotinate | AL622 | [40] |
Purine | AP23464, AP23848, AP23846, AP23994, AP23451, AP23588 | [22] |
Pyrazolopyrimidine | PP1 and PP2 | [22] |
Pyridopyrimidinone | PD180970, PD173955, PD166326 | [22] |
Pyrimidinylaminothiazole | BMS-354825 (Dasatinib) | [22] |
Pyrrolo[2,3-d]pyrimidine | N-Benzyl-7-(4-fluorobenzyl)-2-(methylthio)-7H-pyrrolo[2,3-d]pyrimidin-4-amine | [41] |
Pyrrolopyrimidine | CGP76030 and CGP-76775 | [21] |
Quinazoline | AZM475271 (M475271) and AZD0530 | [21] |
Quinoline | SKI-606 (Bosutinib) | [21] |